- Remove All
- Your shopping cart is currently empty
GalNAc-transferase-7 (GALNT7) is essential for the regulation of cell proliferation and has been implicated in tumorigenesis. Colorectal cancer (CRC) arises in a multistep molecular network process, which is from either discrete genetic perturbation or epigenetic dysregulation. GALNT7 acts as a glycosyltransferase in protein O-glycosylation, involving in the occurrence and development of CRC. GALNT7 silencing significantly attenuated the proliferation, clonogenicity and migration of LSCC cells and induced their cycling arrest. miR-30e may function as tumor suppressors in cervical cancer through downregulation of GALNT7. Both miR-30e and its novel target, GALNT7, may play an important role in the process of cervical cancer.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
50 μg | $361 | In Stock | |
100 μg | $616 | 7-10 days | |
200 μg | $1,050 | 7-10 days | |
500 μg | $2,130 | 7-10 days |
Biological Activity | Activity testing is in progress. It is theoretically active, but we cannot guarantee it. If you require protein activity, we recommend choosing the eukaryotic expression version first. |
Description | GalNAc-transferase-7 (GALNT7) is essential for the regulation of cell proliferation and has been implicated in tumorigenesis. Colorectal cancer (CRC) arises in a multistep molecular network process, which is from either discrete genetic perturbation or epigenetic dysregulation. GALNT7 acts as a glycosyltransferase in protein O-glycosylation, involving in the occurrence and development of CRC. GALNT7 silencing significantly attenuated the proliferation, clonogenicity and migration of LSCC cells and induced their cycling arrest. miR-30e may function as tumor suppressors in cervical cancer through downregulation of GALNT7. Both miR-30e and its novel target, GALNT7, may play an important role in the process of cervical cancer. |
Species | Human |
Expression System | HEK293 Cells |
Tag | C-His |
Accession Number | Q86SF2 |
Synonyms | polypeptide N-acetylgalactosaminyltransferase 7,GALNAC-T7,GalNAcT7 |
Construction | A DNA sequence encoding the human GALNT7 (NP_059119.2) (Pro30-Val657) was expressed with a polyhistidine tag at the C-terminus. Predicted N terminal: Pro 30 |
Protein Purity | > 85 % as determined by SDS-PAGE. |
Molecular Weight | 73.6 kDa (predicted) |
Endotoxin | < 1.0 EU/μg of the protein as determined by the LAL method. |
Formulation | Lyophilized from a solution filtered through a 0.22 μm filter, containing 50 mM Tris, 150 mM NaCl, pH 7.4. Typically, a mixture containing 5% to 8% trehalose, mannitol, and 0.01% Tween 80 is incorporated as a protective agent before lyophilization. |
Reconstitution | A Certificate of Analysis (CoA) containing reconstitution instructions is included with the products. Please refer to the CoA for detailed information. |
Stability & Storage | It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots. |
Shipping | In general, Lyophilized powders are shipping with blue ice. |
Research Background | GalNAc-transferase-7 (GALNT7) is essential for the regulation of cell proliferation and has been implicated in tumorigenesis. Colorectal cancer (CRC) arises in a multistep molecular network process, which is from either discrete genetic perturbation or epigenetic dysregulation. GALNT7 acts as a glycosyltransferase in protein O-glycosylation, involving in the occurrence and development of CRC. GALNT7 silencing significantly attenuated the proliferation, clonogenicity and migration of LSCC cells and induced their cycling arrest. miR-30e may function as tumor suppressors in cervical cancer through downregulation of GALNT7. Both miR-30e and its novel target, GALNT7, may play an important role in the process of cervical cancer. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.